BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 16353147)

  • 1. Inhibition of bone-derived insulin-like growth factors by a ligand-specific antibody suppresses the growth of human multiple myeloma in the human adult bone explanted in NOD/SCID mouse.
    Araki K; Sangai T; Miyamoto S; Maeda H; Zhang SC; Nakamura M; Ishii G; Hasebe T; Kusaka H; Akiyama T; Tokuda Y; Nagai K; Minami H; Ochiai A
    Int J Cancer; 2006 May; 118(10):2602-8. PubMed ID: 16353147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors.
    Goya M; Miyamoto S; Nagai K; Ohki Y; Nakamura K; Shitara K; Maeda H; Sangai T; Kodama K; Endoh Y; Ishii G; Hasebe T; Yonou H; Hatano T; Ogawa Y; Ochiai A
    Cancer Res; 2004 Sep; 64(17):6252-8. PubMed ID: 15342412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blockade of paracrine supply of insulin-like growth factors using neutralizing antibodies suppresses the liver metastasis of human colorectal cancers.
    Miyamoto S; Nakamura M; Shitara K; Nakamura K; Ohki Y; Ishii G; Goya M; Kodama K; Sangai T; Maeda H; Shi-Chuang Z; Chiba T; Ochiai A
    Clin Cancer Res; 2005 May; 11(9):3494-502. PubMed ID: 15867252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roles of osteoclasts and bone-derived IGFs in the survival and growth of human breast cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice.
    Sangai T; Fujimoto H; Miyamoto S; Maeda H; Nakamura M; Ishii G; Nagai K; Nagashima T; Miyazaki M; Ochiai A
    Clin Exp Metastasis; 2008; 25(4):401-10. PubMed ID: 18307047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis.
    Wu KD; Zhou L; Burtrum D; Ludwig DL; Moore MA
    Cancer Immunol Immunother; 2007 Mar; 56(3):343-57. PubMed ID: 16832681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Establishment of multiple myeloma mouse models expressing brain derived neurotrophic factor].
    Wang YD; Hu Y; Zhang L; Huang J; Sun CY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Oct; 15(5):967-72. PubMed ID: 17956671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Monoclonal antibody against brain derived neurotrophic factor inhibits myeloma growth and angiogenesis in the xenograft NOD/SCID animal model].
    Wang YD; Hu Y; Zhang L; Huang J; Sun CY
    Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):659-63. PubMed ID: 18399169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor effect of anti-brain derived neurotrophic factor monoclonal antibody in human multiple myeloma xenograft animal model.
    Wang YD; Hu Y; Huang J; Zhang L; Sun CY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Oct; 16(5):1069-72. PubMed ID: 18928597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
    Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN
    Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NOD/SCID-GAMMA mice are an ideal strain to assess the efficacy of therapeutic agents used in the treatment of myeloma bone disease.
    Lawson MA; Paton-Hough JM; Evans HR; Walker RE; Harris W; Ratnabalan D; Snowden JA; Chantry AD
    PLoS One; 2015; 10(3):e0119546. PubMed ID: 25768011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ligand-specific antibodies to insulin-like growth factors suppress intestinal polyp formation in Apc+/- mice.
    Matsunaka T; Miyamoto S; Shitara K; Ochiai A; Chiba T
    Mol Cancer Ther; 2010 Feb; 9(2):419-28. PubMed ID: 20103605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Control of apoptosis in human multiple myeloma by insulin-like growth factor I (IGF-I).
    Jernberg-Wiklund H; Nilsson K
    Adv Cancer Res; 2007; 97():139-65. PubMed ID: 17419944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871.
    Cohen BD; Baker DA; Soderstrom C; Tkalcevic G; Rossi AM; Miller PE; Tengowski MW; Wang F; Gualberto A; Beebe JS; Moyer JD
    Clin Cancer Res; 2005 Mar; 11(5):2063-73. PubMed ID: 15756033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation.
    Maloney EK; McLaughlin JL; Dagdigian NE; Garrett LM; Connors KM; Zhou XM; Blättler WA; Chittenden T; Singh R
    Cancer Res; 2003 Aug; 63(16):5073-83. PubMed ID: 12941837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of animal models in multiple myeloma.
    Libouban H
    Morphologie; 2015 Jun; 99(325):63-72. PubMed ID: 25898798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteoblasts mediate insulin-like growth factor-I and -II stimulation of osteoclast formation and function.
    Hill PA; Reynolds JJ; Meikle MC
    Endocrinology; 1995 Jan; 136(1):124-31. PubMed ID: 7828521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.
    Burtrum D; Zhu Z; Lu D; Anderson DM; Prewett M; Pereira DS; Bassi R; Abdullah R; Hooper AT; Koo H; Jimenez X; Johnson D; Apblett R; Kussie P; Bohlen P; Witte L; Hicklin DJ; Ludwig DL
    Cancer Res; 2003 Dec; 63(24):8912-21. PubMed ID: 14695208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishment of a novel species- and tissue-specific metastasis model of human prostate cancer in humanized non-obese diabetic/severe combined immunodeficient mice engrafted with human adult lung and bone.
    Yonou H; Yokose T; Kamijo T; Kanomata N; Hasebe T; Nagai K; Hatano T; Ogawa Y; Ochiai A
    Cancer Res; 2001 Mar; 61(5):2177-82. PubMed ID: 11280783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activating Fc receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult t-cell leukemia.
    Zhang M; Zhang Z; Garmestani K; Goldman CK; Ravetch JV; Brechbiel MW; Carrasquillo JA; Waldmann TA
    Cancer Res; 2004 Aug; 64(16):5825-9. PubMed ID: 15313926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential.
    Bieghs L; Johnsen HE; Maes K; Menu E; Van Valckenborgh E; Overgaard MT; Nyegaard M; Conover CA; Vanderkerken K; De Bruyne E
    Oncotarget; 2016 Jul; 7(30):48732-48752. PubMed ID: 27129151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.